IgG antibody subclass responses determined by immunoblot in infants' sera following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine

Vaccine

Volumn 19, Issue 31, 2001, Pages 4404-4408

  Martin, Sarah ^a   Sadler, Francesca ^a   Borrow, Ray ^a   Dawson, Maureen ^b   Fox, Andrew ^a   Cartwright, Keith ^c  

^a WITHINGTON HOSPITAL   (United Kingdom)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^c GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

Neisseria meningitidis; PorA; Vaccine

Indexed keywords

BACTERIAL VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PORIN A; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; BACTERIAL MEMBRANE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; IMMUNOBLOTTING; IMMUNOSTIMULATION; INFANT; MAJOR CLINICAL STUDY; MEMBRANE VESICLE; MENINGOCOCCOSIS; OUTER MEMBRANE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; VACCINATION;

ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOBLOTTING; IMMUNOGLOBULIN G; INFANT; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PORINS; VACCINES, SYNTHETIC;

EID: 0035859986     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00198-0     Document Type: Article

References (24)

1. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory
2. Immunological response of man to group B meningococcal polysaccharide antigens
3. Antigenic similarities between brain components and bacteria causing meningitis: Implications for vaccine development and pathogenesis
4. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
5. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba
6. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile
7. Immune response of Brazilian children of Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy
8. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
9. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 outer membrane proteins
10. Immunogenicity of meningococcal antigens as detected in patient sera
11. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting
12. Serum antibodies to cross-reactive Neisseria outer membrane antigens in healthy persons and patients with meningocococcal disease
13. Human immunity to the meningococcus. I. The role of humoral antibodies
14. The immune response to a N. meningitidis 200 kDa surface exposed protein following carriage and disease
15. Electrophoretic transfer of proteins from polysaccharide gels to nitrocellulose sheets: Procedure and some applications
16. Naturally occurring antibodies in human sera that react with the iron-regulated outer membrane proteins of Escherichia coli
17. Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine
18. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination
19. Quantitation of IgG subclass antibody responses after immunisation with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards
20. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age
21. Opsonophagocytic activity induced by chimeric antibodies to the four human IgG subclasses with or without help from complement
22. The reaction of monomeric and aggregated immunoglobulins with C1